Cite
Müller M, Rösch L, Najafi S, et al. Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers (Basel). 2021;13(17)doi: 10.3390/cancers13174476.
Müller, M., Rösch, L., Najafi, S., Gatzweiler, C., Ridinger, J., Gerloff, X. F., Jones, D. T. W., Baßler, J., Kreth, S., Stainczyk, S., Frese, K., Meder, B., Westermann, F., Milde, T., Peterziel, H., Witt, O., & Oehme, I. (2021). Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers, 13(17), . https://doi.org/10.3390/cancers13174476
Müller, Michael, et al. "Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma." Cancers vol. 13,17 (2021). doi: https://doi.org/10.3390/cancers13174476
Müller M, Rösch L, Najafi S, Gatzweiler C, Ridinger J, Gerloff XF, Jones DTW, Baßler J, Kreth S, Stainczyk S, Frese K, Meder B, Westermann F, Milde T, Peterziel H, Witt O, Oehme I. Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers (Basel). 2021 Sep 05;13(17). doi: 10.3390/cancers13174476. PMID: 34503286; PMCID: PMC8431508.
Copy
Download .nbib